Onyx Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Onyx Pharmaceuticals (ONXX)
Q2 2012 Earnings Call
August 01, 2012 5:00 pm ET
Executives
Amy FigueroaN. Anthony Coles - Chief Executive Officer, President and DirectorHelen Torley - Chief Commercial officer and Executive Vice PresidentMatthew K. Fust - Chief Financial Officer, Principal Accounting Officer and Executive Vice PresidentBarbara KlenckeAnalystsMichael G. King - Rodman & Renshaw, LLC, Research DivisionCory William Kasimov - JP Morgan Chase & Co, Research DivisionTerence C. Flynn - Goldman Sachs Group Inc., Research DivisionRachel L. McMinn - BofA Merrill Lynch, Research DivisionHoward Liang - Leerink Swann LLC, Research DivisionBiren Amin - Jefferies & Company, Inc., Research DivisionMatthew R. Wooten - Robert W. Baird & Co. Incorporated, Research DivisionNavdeep Singh - Deutsche Bank AG, Research DivisionGeoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research DivisionLing Wang - Summer Street Research PartnersEcho Yinghui He - Maxim Group LLC, Research DivisionRyan Martins - Lazard Capital Markets LLC, Research DivisionNicholas Bishop - Cowen and Company, LLC, Research DivisionYing Huang - Barclays Capital, Research DivisionMarshall Urist - Morgan Stanley, Research DivisionJim Birchenough - BMO Capital Markets U.S.PresentationOperatorPrevious Statements by ONXX
» Onyx Pharmaceuticals Inc. Q2 2009 Earnings Call Transcript
» Onyx Pharmaceuticals Inc. Q1 2009 Earnings Call Transcript
» Onyx Pharmaceuticals, Inc., Q4 2008 Earnings Call Transcript
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
